<p>Waterloo Capital L.P. 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度收购了 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的新股份。该机构投资者收购了 3,929 股该制药公司的股票，价值约为 1,781,000 美元。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>CRISPR Therapeutics 在财报发布后股价上涨，管道希望增加</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也对该股票的持仓进行了调整。Danske Bank A S 在第三季度购买了价值约 64,417,000 美元的 Vertex Pharmaceuticals 新股份。三菱 UFJ 资产管理有限公司在第三季度将其在 Vertex Pharmaceuticals 的持仓提高了 3.8%。三菱 UFJ 资产管理有限公司目前拥有 544,978 股该制药公司的股票，价值 213,435,000 美元，此前在上个季度又购买了 20,053 股。Leuthold Group LLC 在第三季度购买了价值约 5,030,000 美元的 Vertex Pharmaceuticals 新股份。Legacy Capital Group California Inc. 在第三季度购买了价值约 956,000 美元的 Vertex Pharmaceuticals 新股份。最后，ING Groep NV 在第三季度购买了价值约 4,695,000 美元的 Vertex Pharmaceuticals 新股份。机构投资者持有该公司 90.96% 的股票。</p>
<h2>Vertex Pharmaceuticals 股票表现</h2>
<p>Vertex Pharmaceuticals 股票周一开盘价为 447.54 美元。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 362.50 美元，1 年最高价为 507.92 美元。该公司的市值为 1,135.9 亿美元，市盈率为 26.54，市盈率/增长比率为 1.92，贝塔值为 0.30。该公司的 50 日简单移动平均线为 439.06 美元，200 日简单移动平均线为 451.85 美元。</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近于 5 月 4 日发布了季度财报。该制药公司报告每股收益为 4.47 美元，超出分析师共识预期的 4.24 美元，超出幅度为 0.23 美元。Vertex Pharmaceuticals 的净利润率为 35.51%，股本回报率为 23.86%。该公司在本季度的收入为 29.9 亿美元，而分析师预期的收入也是 29.9 亿美元。在去年同期，该公司的每股收益为 4.06 美元。与去年同期相比，Vertex Pharmaceuticals 的收入增长了 8.3%。平均而言，股票研究分析师预测 Vertex Pharmaceuticals Incorporated 在当前年度将发布 16.99 的每股收益。</p>
<h2>Vertex Pharmaceuticals 的内部买卖</h2>
<p>在其他 Vertex Pharmaceuticals 的新闻中，执行副总裁 Joy Liu 于 5 月 1 日星期五出售了 1,104 股该公司的股票。股票以平均价格 425.02 美元出售，总价值为 469,222.08 美元。交易完成后，该执行副总裁直接持有 20,729 股公司的股票，价值 8,810,239.58 美元。这笔交易代表其持仓减少了 5.06%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Sangeeta N. Bhatia 于 5 月 4 日星期一出售了 318 股该公司的股票。股票以平均价格 423.73 美元出售，总交易额为 134,746.14 美元。交易完成后，该董事直接持有 4,924 股公司的股票，价值约 2,086,446.52 美元。这笔交易使其持股减少了 6.07%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内共出售了价值 5,309,945 美元的 11,717 股公司股票。公司内部人士持有公司 0.20% 的股票。</p>
<h2>华尔街分析师的看法</h2>
<ul>
<li>2025 年最佳生物技术股票</li>
</ul>
<p>VRTX 已成为多份研究分析师报告的主题。华尔街 Zen 在周六的一份研究报告中将 Vertex Pharmaceuticals 的股票评级从 &#34;买入&#34; 下调至 &#34;持有&#34;。杰富瑞金融集团在 3 月 10 日星期二的一份研究报告中开始覆盖 Vertex Pharmaceuticals 的股票。他们给予该公司 &#34;买入&#34; 评级，并设定 580.00 美元的目标价。花旗集团在 3 月 10 日星期二将 Vertex Pharmaceuticals 的目标价从 575.00 美元上调至 585.00 美元，并给予该股票 &#34;买入&#34; 评级。桑福德 C. 伯恩斯坦在 5 月 5 日星期二将 Vertex Pharmaceuticals 的目标价从 577.00 美元下调至 572.00 美元，并在一份研究报告中给予该公司 &#34;跑赢大盘&#34; 评级。最后，美国银行在 3 月 10 日星期二将 Vertex Pharmaceuticals 的目标价从 571.00 美元上调至 598.00 美元，并给予该股票 &#34;买入&#34; 评级。22 位投资分析师对该股票给予了 &#34;买入&#34; 评级，3 位分析师给予了该公司股票 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，平均目标价为 555.91 美元。</p>
<p><strong>获取我们关于 Vertex Pharmaceuticals 的最新股票分析</strong></p>
<h2>关于 Vertex Pharmaceuticals</h2>
<p>(免费报告)</p>
<p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病的治疗方法的发现、开发和商业化。公司成立于 1989 年，凭借以研究为驱动的药物开发建立了声誉，最为人知的是在囊性纤维化（CF）领域的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
<p>Vertex 的市场产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>这三只 CLO ETF 瞄准固定收益市场的细分领域</li>
<li>三种方式参与数据中心土地争夺战</li>
<li>更聪明的投资 AI 方式，无需承担极端风险</li>
<li>三只每季度都能赢得王冠的股息之王</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>Waterloo Capital L.P. 在第四季度收购了价值 178 万美元的 Vertex Pharmaceuticals (VRTX) 新头寸，购买了 3,929 股，具体信息见其 SEC 13F 表格。其他机构投资者如丹斯克银行和三菱 UFJ 也增加了他们的持股。同时，内部人士执行副总裁 Joy Liu 和董事 Sangeeta N. Bhatia 根据 10b5-1 规则出售了股份。分析师们总体上持乐观态度，杰富瑞开始覆盖，目标价为 580 美元，尽管华尔街 Zen 将 VRTX 评级下调至 “持有”</p>

<p>Waterloo Capital L.P. acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,929 shares of the pharmaceutical company's stock, valued at approximately $1,781,000.</p>
<div class="lb-trans"><p>Waterloo Capital L.P. 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度收购了 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的新股份。该机构投资者收购了 3,929 股该制药公司的股票，价值约为 1,781,000 美元。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 在财报发布后股价上涨，管道希望增加</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Danske Bank A S bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $64,417,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Vertex Pharmaceuticals by 3.8% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company's stock worth $213,435,000 after buying an additional 20,053 shares in the last quarter. Leuthold Group LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $5,030,000. Legacy Capital Group California Inc. bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $956,000. Finally, ING Groep NV bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $4,695,000. Institutional investors own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也对该股票的持仓进行了调整。Danske Bank A S 在第三季度购买了价值约 64,417,000 美元的 Vertex Pharmaceuticals 新股份。三菱 UFJ 资产管理有限公司在第三季度将其在 Vertex Pharmaceuticals 的持仓提高了 3.8%。三菱 UFJ 资产管理有限公司目前拥有 544,978 股该制药公司的股票，价值 213,435,000 美元，此前在上个季度又购买了 20,053 股。Leuthold Group LLC 在第三季度购买了价值约 5,030,000 美元的 Vertex Pharmaceuticals 新股份。Legacy Capital Group California Inc. 在第三季度购买了价值约 956,000 美元的 Vertex Pharmaceuticals 新股份。最后，ING Groep NV 在第三季度购买了价值约 4,695,000 美元的 Vertex Pharmaceuticals 新股份。机构投资者持有该公司 90.96% 的股票。</p>
</div><h2>Vertex Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票表现</h2>
</div><p>Vertex Pharmaceuticals stock opened at $447.54 on Monday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $507.92. The firm has a market capitalization of $113.59 billion, a price-to-earnings ratio of 26.54, a P/E/G ratio of 1.92 and a beta of 0.30. The firm has a 50 day simple moving average of $439.06 and a 200 day simple moving average of $451.85.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 股票周一开盘价为 447.54 美元。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 362.50 美元，1 年最高价为 507.92 美元。该公司的市值为 1,135.9 亿美元，市盈率为 26.54，市盈率/增长比率为 1.92，贝塔值为 0.30。该公司的 50 日简单移动平均线为 439.06 美元，200 日简单移动平均线为 451.85 美元。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating analysts' consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same period in the previous year, the business earned $4.06 EPS. Vertex Pharmaceuticals's revenue was up 8.3% compared to the same quarter last year. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.99 EPS for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近于 5 月 4 日发布了季度财报。该制药公司报告每股收益为 4.47 美元，超出分析师共识预期的 4.24 美元，超出幅度为 0.23 美元。Vertex Pharmaceuticals 的净利润率为 35.51%，股本回报率为 23.86%。该公司在本季度的收入为 29.9 亿美元，而分析师预期的收入也是 29.9 亿美元。在去年同期，该公司的每股收益为 4.06 美元。与去年同期相比，Vertex Pharmaceuticals 的收入增长了 8.3%。平均而言，股票研究分析师预测 Vertex Pharmaceuticals Incorporated 在当前年度将发布 16.99 的每股收益。</p>
</div><h2>Insider Buying and Selling at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的内部买卖</h2>
</div><p>In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of the firm's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the transaction, the executive vice president directly owned 20,729 shares of the company's stock, valued at $8,810,239.58. This trade represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the firm's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the transaction, the director directly owned 4,924 shares of the company's stock, valued at approximately $2,086,446.52. The trade was a 6.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,717 shares of company stock valued at $5,309,945 in the last three months. Company insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Vertex Pharmaceuticals 的新闻中，执行副总裁 Joy Liu 于 5 月 1 日星期五出售了 1,104 股该公司的股票。股票以平均价格 425.02 美元出售，总价值为 469,222.08 美元。交易完成后，该执行副总裁直接持有 20,729 股公司的股票，价值 8,810,239.58 美元。这笔交易代表其持仓减少了 5.06%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Sangeeta N. Bhatia 于 5 月 4 日星期一出售了 318 股该公司的股票。股票以平均价格 423.73 美元出售，总交易额为 134,746.14 美元。交易完成后，该董事直接持有 4,924 股公司的股票，价值约 2,086,446.52 美元。这笔交易使其持股减少了 6.07%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内共出售了价值 5,309,945 美元的 11,717 股公司股票。公司内部人士持有公司 0.20% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票</li>
</ul>
</div><p>VRTX has been the subject of several research analyst reports. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Jefferies Financial Group initiated coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 10th. They set a &#34;buy&#34; rating and a $580.00 price target for the company. Citigroup raised their price target on shares of Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 10th. Sanford C. Bernstein decreased their price target on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an &#34;outperform&#34; rating for the company in a research note on Tuesday, May 5th. Finally, Bank of America raised their price target on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 10th. Twenty-two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $555.91.</p>
<div class="lb-trans"><p>VRTX 已成为多份研究分析师报告的主题。华尔街 Zen 在周六的一份研究报告中将 Vertex Pharmaceuticals 的股票评级从 &#34;买入&#34; 下调至 &#34;持有&#34;。杰富瑞金融集团在 3 月 10 日星期二的一份研究报告中开始覆盖 Vertex Pharmaceuticals 的股票。他们给予该公司 &#34;买入&#34; 评级，并设定 580.00 美元的目标价。花旗集团在 3 月 10 日星期二将 Vertex Pharmaceuticals 的目标价从 575.00 美元上调至 585.00 美元，并给予该股票 &#34;买入&#34; 评级。桑福德 C. 伯恩斯坦在 5 月 5 日星期二将 Vertex Pharmaceuticals 的目标价从 577.00 美元下调至 572.00 美元，并在一份研究报告中给予该公司 &#34;跑赢大盘&#34; 评级。最后，美国银行在 3 月 10 日星期二将 Vertex Pharmaceuticals 的目标价从 571.00 美元上调至 598.00 美元，并给予该股票 &#34;买入&#34; 评级。22 位投资分析师对该股票给予了 &#34;买入&#34; 评级，3 位分析师给予了该公司股票 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，平均目标价为 555.91 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Vertex Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>About Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Vertex Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病的治疗方法的发现、开发和商业化。公司成立于 1989 年，凭借以研究为驱动的药物开发建立了声誉，最为人知的是在囊性纤维化（CF）领域的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
</div><p>Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.</p>
<div class="lb-trans"><p>Vertex 的市场产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market</li>
<li>3 Ways to Play the Data Center Land Grab</li>
<li>The Smarter Way to Invest in AI Without Taking Extreme Risk</li>
<li>3 Dividend Kings That Earn Their Crown Every Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>这三只 CLO ETF 瞄准固定收益市场的细分领域</li>
<li>三种方式参与数据中心土地争夺战</li>
<li>更聪明的投资 AI 方式，无需承担极端风险</li>
<li>三只每季度都能赢得王冠的股息之王</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Waterloo Capital L.P. Invests $1.78 Million in Vertex Pharmaceuticals Incorporated $VRTX

Market Beat

CRISPR治疗

Waterloo Capital L.P. 向 Vertex Pharmaceuticals Incorporated（福泰制药）投资了 178 万美元